[]
Kwan P., Brodie, M.J.: Effectiveness of first antiepileptic drug. Epilepsia
2001; 42: 1255–1260.
[]
Stolarek I., Blacklaw J., Forrest G., et al.: Vigabatrin and lamotrigine in
refractory epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 921–924.
[]
Pina-Garza J.E., Espinoza R., Nordli D., et al.: Oxcarbazepine adjunctive
therapy in infants and young children with partial seizures. Neurology
2005; 65: 1370–1375.
[]
Li J., Xiao N., Chen, S.: Efficacy and tolerability of levetiracetam in
children with epilepsy. Brain Dev 33: 145–151.
[]
Obeid M., Pong A.W.: Efficacy and tolerability of high oral doses of
levetiracetam in children with epilepsy. Epilepsy Res 91: 101–105.
[]
Coppola G., Mangano S., Tortorella G., et al.: Levetiracetam during 1-year
follow-up in children, adolescents, and young adults with refractory
epilepsy. Epilepsy Res 2004; 59: 35–42.
[]
Peake D., Mordekar S., Gosalakkal J., et al.: Retention rate of
levetiracetam in children with intractable epilepsy at 1 year. Seizure
2007; 16: 185–189.
[]
Chappell B., Crawford P.: An audit of lamotrigine, levetiracetam and
topiramate usage for epilepsy in a district general hospital. Seizure 2005;
14: 422–428.
[]
Rosenow F., Schade-Brittinger C., Burchardi N., et al.: The LaLiMo
Trial: lamotrigine compared with levetiracetam in the initial 26 weeks
of monotherapy for focal and generalised epilepsy--an open-label,
prospective, randomised controlled multicenter study. J Neurol
Neurosurg Psychiatry 83: 1093–1098.
[]
Baulac M., Leon T., O’Brien T.J., et al.: A comparison of pregabalin,
lamotrigine, and placebo as adjunctive therapy in patients with refractory
partial-onset seizures. Epilepsy Res 91: 10–19.
[]
Camfield P., Camfield C., Smith S., et al.: Long-term outcome is
unchanged by antiepileptic drug treatment after a first seizure: a 15-year
follow-up from a randomized trial in childhood. Epilepsia 2002; 43: 662–
663.
[]
Ding Y.X., Zou L.P., Ma M.S., et al.: Retrospective analysis of the
effectiveness of first-line antiepileptic drugs for generalized onset and
unclassified epileptic seizures in Chinese children. Childs Nerv Syst 27:
279–284.
[]
Elger C.E., Fernandez G.: Options after the first antiepileptic drug has
failed. Epilepsia 1999; 40 Suppl 6:S9-12; discussion 73–14.
[]
Loscher W., Schmidt D.: Experimental and clinical evidence for loss of
effect (tolerance) during prolonged treatment with antiepileptic drugs.
Epilepsia 2006; 47: 1253–1284.
[]
Nonoda Y., Iwasaki T., Ishii M.: The efficacy of gabapentin in children of
partial seizures and the blood levels. Brain Dev 36: 194–202.
[]
Appleton R., Fichtner K., LaMoreaux L., et al.: Gabapentin as add-on
therapy in children with refractory partial seizures: a 24-week,
multicentre, open-label study. Dev Med Child Neurol 2001; 43: 269–273.
[]
Khan R.B., Hunt D.L.,Thompson S.J.: Gabapentin to control seizures in
children undergoing cancer treatment. J Child Neurol 2004; 19: 97–101.
[]
Lindberger M., Alenius M., Frisen L., et al.: Gabapentin versus vigabatrin
as first add-on for patients with partial seizures that failed to respond to
monotherapy: a randomized, double-blind, dose titration study. GREAT
Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on
Treatment. Epilepsia 2000; 41: 1289–1295.
[]
Schmidt D., Gram L., Brodie M., et al.: Tiagabine in the treatment of
epilepsy – a clinical review with a guide for the prescribing physician.
Epilepsy Res 2000; 41: 245–251.
[]
Arroyo S., Boothman B.R., Brodie M.J., et al.: A randomised open-label
study of tiagabine given two or three times daily in refractory epilepsy.
Seizure 2005; 14: 81–84.
[]
Genton P., Guerrini R., Perucca, E.: Tiagabine in clinical practice. Epilepsia
2001; 42 Suppl 3: 42–45.
[]
Balslev T., Uldall P., Buchholt J.: Provocation of non-convulsive status
epilepticus by tiagabine in three adolescent patients. Eur J Paediatr
Neurol 2000; 4: 169–170.
[]
Uldall P., Bulteau C., Pedersen S.A., et al.: Tiagabine adjunctive therapy
in children with refractory epilepsy: a single-blind dose escalating study.
Epilepsy Res 2000; 42: 159–168.
[]
Bauer J., Bergmann A., Reuber M., et al.: Tolerability of tiagabine:
a prospective open-label study. Epileptic Disord 2002; 4: 257–260.
[]
Jedrzejczak J.: Tiagabine as add-on therapy may be more effective
with valproic acid--open label, multicentre study of patients with focal
epilepsy. Eur J Neurol 2005; 12:176–180.
[]
Knoester P.D., Keyser A., Renier W.O., et al.: Effectiveness of lamotrigine
in clinical practice: results of a retrospective population-based study.
Epilepsy Res 2005; 65: 93–100.
[]
Friedlander W.J.: Who was ‚the father of bromide treatment of epilepsy’? Arch Neurol 1986; 43: 505-507.
[]
Lopez-Munoz F., Ucha-Udabe R., Alamo C.: The history of barbiturates
a century after their clinical introduction. Neuropsychiatr Dis Treat 2005; 1: 329–343.
[]
Dodson W.E., Fish D.R., Perucca E., et al.: The Treatment of epilepsy
[print], 2nd ed., Blackwell Science, Malden, MA, 2004.
[]
Reynolds E.H.: Milestones in epilepsy*. Epilepsia 2009; 50: 338–342.
[]
Cretin B., Hirsch E.: Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last. Expert Opin Pharmacother 2010; 11: 1053–1067.
[]
Loscher W., Schmidt D.: Modern antiepileptic drug development has
failed to deliver: ways out of the current dilemma. Epilepsia 2010; 52: 657–678.
[]
Schmidt D.: Efficacy of new antiepileptic drugs. 2011 Epilepsy Curr 11: 9–11.
[]
Mazurkiewicz-Bełdzińska M.: Skuteczność, objawy niepożądane i wpływ
na jakość życia nowych leków przeciwpadaczkowych w terapii padaczki
u dzieci i młodzieży – praca habilitacyjna Annales Acad Med Ged 2011;
XLV.
[]
Ben-Menachem E., Sander J.W., Privitera M., et al.: Measuring
outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy
Behav 2011; 18: 24–30.
[]
European Medicines Agency (EMEA) Guideline on clinical investigation
of medicinal products inthe treatment of epileptic disorders. CHMP/
EWP/566/98/Rewizja: 2. Styczeń 2010.
[]
Duchowny M., Pellock J.M., Graf W.D., et al.: A placebo-controlled trial
of lamotrigine add-on therapy for partial seizures in children. Lamictal
Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–1731.
[]
Lhatoo S.D., Wong I.C., Polizzi G., et al.: Long-term retention rates of
lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia
2000; 41: 1592–1596.
[]
Eadie M.J.: Cortical epileptogenesis--Hughlings Jackson and his predecessors. Epilepsia 2007; 48: 2010-2015.
[]
Besag F.M., Wallace S. J., Dulac O., et al.: Lamotrigine for the treatment
of epilepsy in childhood. J Pediatr 1995; 127: 991–997.
[]
Kluger G., Berz K., Holthausen H.: The long-term use of vigabatrin and
lamotrigine in patients with severe childhood onset epilepsy. Eur J
Paediatr Neurol 2001; 5: 37–40.
[]
Motte J., Trevathan E., Arvidsson J.F., et al.: Lamotrigine for generalized
seizures associated with the Lennox-Gastaut syndrome. Lamictal
Lennox-Gastaut Study Group. N Engl J Med 1997; 337: 1807–1812.
[]
Stenbom Y., Tonnby B., Hagberg, B.: Lamotrigine in Rett syndrome:
treatment experience from a pilot study. Eur Child Adolesc Psychiatry
1998; 7: 49–52.
[]
Cianchetti C., Pruna D., Coppola G., et al.: Low-dose lamotrigine in West
syndrome. Epilepsy Res 2002; 51: 199–200.
[]
Aberg L., Heiskala H., Vanhanen, S.L., et al.: Lamotrigine therapy in
infantile neuronal ceroid lipofuscinosis (INCL). Neuropediatrics 1997;
28: 77–79.
[]
Fakhoury T.A., Hammer A.E., Vuong A., et al.: Efficacy and tolerability of
conversion to monotherapy with lamotrigine compared with valproate
and carbamazepine in patients with epilepsy. Epilepsy Behav 2004; 5:
532–538.
[]
Mazurkiewicz-Beldzinska M., Szmuda M., Matheisel A.: Long-term
efficacy of valproate versus lamotrigine in treatment of idiopathic
generalized epilepsies in children and adolescents. Seizure 2010; 19:
195–197.
[]
Grosso S., Franzoni E., Iannetti P., et al.: Efficacy and safety of topiramate
in refractory epilepsy of childhood: long-term follow-up study. J Child
Neurol 2005; 20: 893–897.
[]
Unalp A., Uran N., Hizli T., et al.: Topiramate as a long-term therapy in
children with refractory epilepsy. Neurosciences (Riyadh) 2008; 13:
391–394.
[]
Glauser T.A., Levisohn P.M., Ritter F., et al.: Topiramate in Lennox-Gastaut
syndrome: open-label treatment of patients completing a randomized
controlled trial. Topiramate YL Study Group. Epilepsia 2000; 41 Suppl 1:
86–90.
Scholar Google
PubMed